Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.elsevier.com/locate/jobcr

Review Article

Periodontal associations in cardiovascular diseases: The latest evidence and understanding

C.M. Nguyen^a, J.W.M. Kim^b, V.H. Quan^c, B.H. Nguyen^d, S.D. Tran^{a,*}^a Faculty of Dentistry, McGill University, Montreal, Canada^b Private Office, Richmond, Canada^c Department of Cardiology, Centre Hospitalier de l'Université de Montreal, Montreal, Canada^d Department of Pediatrics, CHU Sainte-Justine, University of Montreal, Montreal, Canada

ARTICLE INFO

Article history:

Received 11 June 2015

Accepted 27 June 2015

Available online 29 July 2015

Keywords:

Cardiovascular diseases

Periodontal disease

Systemic inflammation

Oral pathogens

Inflammatory cytokines

ABSTRACT

Periodontal and cardiovascular diseases (CVD) are inflammatory diseases. Recent epidemiological studies have associated the effect of periodontitis on CVD progression. Findings of oral pathogens in carotid atheromas provided a plausible relationship between these two diseases. One possible mechanism is the infiltration of oral/periodontal pathogens through inflamed and ulcerated gingival epithelium. This results in translocation of oral pathogens throughout the systemic circulation affecting vascular tissues, and initiating a cascade of inflammatory reactions detrimental to the cardiovascular system. In addition, leakage of pro-inflammatory cytokines/chemokines from the ulcerated periodontium into the bloodstream may cause the production of hepatic acute-phase proteins. Moreover, as chronic bacteremia occurs, the adaptive immune system is activated. Antibodies produced in response to periodontal pathogens trigger a cross-reaction between endothelial cells and modified low-density lipoprotein to enhance the movement of lipids into cells within the vessel wall. Some antibodies and inflammatory cytokines promote the Th1 response, thereby further activating macrophages within the atheroma. These plausible mechanisms are contributing factors in initiating and propagating atherogenesis. This review discusses the current understanding of CVD pathology/periodontitis, potential underlying mechanisms regarding this association, and general guidelines for treating patients with CVD risks.

© 2015 Craniofacial Research Foundation. Published by Elsevier B.V. All rights reserved.

1. Introduction

Cardiovascular disease (CVD) encompasses diseases affecting the heart and/or blood vessels. Atherosclerosis, or arteriosclerotic vascular disease, is a condition whereby progressive plaque (atheroma) buildup occurs in the midsize to large

arteries due to endothelial damage and activation of the host's immune system's inflammatory response.¹ Atherosclerotic lesions can lead to thromboembolism in the brain, heart, and other distal sites, resulting in stroke and infarction. According to the World Health Organization (WHO), cardiovascular diseases are projected to continue to be the single leading cause of death in men and women around the world.²

* Corresponding author.

E-mail address: simon.tran@mcgill.ca (S.D. Tran).<http://dx.doi.org/10.1016/j.jobcr.2015.06.008>

2212-4268/© 2015 Craniofacial Research Foundation. Published by Elsevier B.V. All rights reserved.

Periodontal disease refers to bacteria-induced, chronic inflammatory diseases that destroy the structures supporting the dentition.^{3,4} The two most common forms of periodontal disease are gingivitis and periodontitis. The former is localized to the soft tissues surrounding the teeth and can readily be reversed with treatment. However, periodontitis results in irreversible damage to the attachment apparatus of teeth.^{4,5} With its latest associations to CVD, and many other systemic conditions (such as diabetes), periodontitis has a large impact on the patient's quality of life and poses a high financial burden not only to the patient but also to the society as well.³

As both CVD and periodontitis are multifactorial inflammatory conditions with many shared confounding factors (smoking, obesity, type 2 diabetes), the key link between the two conditions is the propagating impacts of inflammation on the progression of the diseases.^{3,5,6} It is broadly perceived that the inflamed and ulcerated subgingival epithelium in periodontitis allows for the entry of oral bacteria and/or bacterial components into the blood stream which leads to the increased risk and progression of CVD.⁵ Lockhart et al., an American Heart Association (AHA) group, established that although there is currently no evidence of a causal relationship, there exists an association between periodontal disease and atherosclerotic vascular disease independent of known confounders.⁷

2. Overview of atherosclerotic cardiovascular disease (ACVD) pathology

Atherosclerosis is initiated by damage to vessel endothelium. Following injury, there is an increase in platelet aggregation and leukocyte migration as a result of an upregulation of adhesion molecule expression (ICAM-1, VCAM-1, E-selectin, P-selectin) as well as chemoattractants (IL-8, thrombin) by endothelial proinflammatory signals.^{5,6} These proinflammatory signals also initiate smooth muscle cell proliferation and endothelial cell apoptosis. Migrated leukocytes further release proinflammatory cytokines (IL-1, IL-6, TNF α) and release reactive oxygen species (ROS) and proteinases that destroy the endothelium extracellular matrix.^{5,6} Low-density lipoproteins (LDL) accumulate under the intima layer of the endothelium and are subsequently phagocytized by macrophages to become foam cells. Foam cell formation further increases the release of pro-inflammatory cytokines IL-1, IL-6, and TNF α .^{1,6} Meanwhile, smooth muscle cells in between the intima and media layer of the vessels secrete metalloproteinases⁸ (MMPs) that promote myogenesis. The growth of smooth muscle cells causes fibrosis and formation of a fibrous plaque. Over time, cholesterol deposits upon the plaque and forms lipid streaks that can occlude the vessel. Rupture of the plaque releases thrombotic factors that initiate coagulation when in contact with platelets and can cause a thromboembolism.

3. The effects of periodontitis on ACVD

As previously mentioned, acute- and chronic-systemic inflammation has been shown to have pro-atherogenic effects. Periodontal bacteria can affect all of the discussed processes

through a direct interaction (i.e. invading the endothelial cells, smooth muscle cells, leukocytes, and platelets) and/or indirectly through the stimulation of paracrine factor release that ultimately affect cell function (Fig. 1). In the case of periodontitis, once bacteremia occurs, oral pathogens can invade endothelial cells and cause dysfunction. In addition to direct invasion, periodontal bacteria can release products and components into the circulation and induce pro-atherogenic responses in endothelial cells. It has been shown that outer membrane vesicles,⁹ gingipains from *Porphyromonas gingivalis*,¹⁰ and free soluble bacterial components from *Aggregatibacter actinomycetemcomitans*¹¹ irritate endothelial cells and induce inflammation. Leakage of pro-inflammatory cytokines (IL-1, IL-6, TNF α) and other chemokines from the ulcerated periodontium causes the production of acute-phase proteins (i.e. CRP, fibrinogen, amyloid A protein, etc.) by the liver.^{5,6} Moreover, as chronic bacteremia occurs, the adaptive immune system is activated in response. Antibodies that are produced in response to pathogen associated molecular patterns (PAMPs) of periodontal pathogens can trigger a cross-reaction between endothelial cells and modified LDL to enhance the movement of lipids into cells within the vessel wall. Some of these antibodies and inflammatory cytokines can promote the Th1 response, thereby further activating macrophages within the atheroma, and propagating atherogenesis.^{5,6}

4. Recommendations for clinical practitioners

Recent reviews reveal moderate evidence of the long-term positive effects of periodontal treatment on systemic inflammation levels elucidated through the measurement of C reactive protein (CRP) levels, a marker for systemic inflammation and clinical measures of endothelium function. CRP remains to be the established marker of CVD risk.^{3,12,13} In absence of systemic inflammation, high sensitivity CRP level of 1 mg/L indicates a lower risk of CVD, while a level of 3 mg/L indicates an approximate doubling in CVD risk.¹⁴ It is not unusual for patients to have a transient increase in systemic inflammatory mediators and a decrease in endothelial function following non-surgical periodontal treatment within a period of 1 month.¹² However, following this period, these levels will progressively decrease, showing a reduction in basal CRP levels by 6 months.¹² A meta-analysis done in 2012 of four most recent clinical intervention trials reports a 0.23 mg/L reduction ($p < 0.0001$) in CRP levels of patients with periodontitis 2–6 months post-periodontal therapy.¹⁵ Furthermore, patients diagnosed with CVD showed a considerable reduction of CRP from 2.7 ± 1.9 to 1.8 ± 0.9 mg/L ($p < 0.05$) 6 months post-periodontal therapy.¹⁶ With the high number of patients affected by the two diseases, it becomes imperative for practitioners to be informed and aware of the increasing supporting evidence pointing to periodontal disease as a risk factor for ACVD. Therefore, some general clinical guidelines to be considered when treating these patients are as follows³:

1. Proper periodontal disease diagnosis and treatment:

Recognizing the periodontal health status of patients is critical, as the severity of the periodontal disease correlates with the risk level of developing ACVD. The diagnosis and

Fig. 1 – The biologically plausible mechanisms for periodontitis as a risk factor for atherogenesis. There are two pathways that can occur simultaneously by which periodontal infection can affect atherogenesis. In the direct pathway, bacteria infiltrate into the systemic circulation (circle 2) from chronic periodontal infection (shown by circle 1) and penetrate the vascular endothelium causing injury. This in turn triggers the host's inflammatory response, thereby causing the acute-phase response, dyslipidemia (circle 3a) and activation of the adaptive immune system (circle 3b). Plasma cells recognizing the Pathogen associated molecular patterns (PAMPs) of the circulating bacteria release antibodies that can cross react with endothelium and LDL causing more lipids to migrate into endothelial cells (circle 3b). In addition, released antibodies can trigger the Th1 response and enhance macrophage proliferation and migration (circle 3b). In the indirect pathway, bacterial endotoxins and/or pro-inflammatory cytokines disseminate in the bloodstream (circle 2). Similar to the direct pathway, the circulation of these peptides triggers inflammation (IL-1, IL-6, TNF α , PGE $_2$). In response, the liver initiates an acute-phase response, releasing CRP, fibrinogen, amyloid A protein, and many other mediators into circulation (circle 3a). In addition, there is an increase in cholesterol synthesis as a disruption in lipid balance occurs. Furthermore, the chemokines released from the bacteria target leukocytes and lymphocytes from both the innate and adaptive immune systems and initiate cell migration and activity. In response, antibodies are released into circulation (circle 3b) and there is an upregulation of macrophages. Both pathways, direct and indirect, lead to Atherogenesis and/or exacerbation of atherothrombotic lesions (circle 4).

Picture created by CM Nguyen.

severity assignment of the periodontal disease can be achieved by using a periodontal probe to measure clinical attachment levels and check for the presence of inflammation, and performing radiographic assessments.¹⁷

Patients with a history of cardiovascular events should be required to follow AHA guidelines for dental procedures.

2. Determination of other risk factors for ACVD and medical consultation:

Patients who are overweight/obese, smokers, diabetics, hypertensive, or who have other risks factors for ACVD should have routine medical assessments to rule out compounding factors and receive necessary treatments to minimize their risk of ACVD. Alternatively, physicians should consider referring such patients to dentists to provide necessary periodontal treatments.

3. Education of the patient concerning the strong periodontal association in ACVD and the plausible mechanism of bacteremia and increased systemic inflammation.

4. Comprehensive periodontal therapy and lifestyle modification:

As the lifestyle risk factors for periodontal disease and CVD development are very similar, recommendations and advice for changing lifestyle, such as diet, exercise, and smoking cessation, may prove to be beneficial both orally and systemically.

5. Conclusion

There is surmounting evidence of an association between periodontitis and cardiovascular disease. With recent epidemiological, clinical, and experimental evidence, the proposed mechanism of bacteremia inducing pro-atherogenic lesions is further supported. The guidelines for clinical practitioners serve as a general preliminary and precautionary measure

as there is evidence that proper periodontal treatment reduces systemic inflammation levels and there exists a relationship between inflammation and atherogenesis. In order to determine the exact biological mechanism and confirm a direct or causal relationship, more interventional and longitudinal studies are needed.

Conflicts of interest

The authors have none to declare.

REFERENCES

- Mitchell ME, Sidawy AN. The pathophysiology of atherosclerosis. *Semin Vasc Surg.* 1998;11(3):134–141.
- Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. *PLoS Med.* 2006;3(11):e442.
- Tonetti MS, Van Dyke TE. Periodontitis and atherosclerotic cardiovascular disease: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. *J Periodontol.* 2013;84(4 suppl):S24–S29.
- Lindhe J, Haffajee AD, Socransky SS. Progression of periodontal disease in adult subjects in the absence of periodontal therapy. *J Clin Periodontol.* 1983;10(4):433–442.
- Van Dyke TE, van Winkelhoff AJ. Infection and inflammatory mechanisms. *J Periodontol.* 2013;84(4 suppl):S1–S7.
- Schenkein HA, Loos BG. Inflammatory mechanisms linking periodontal diseases to cardiovascular diseases. *J Periodontol.* 2013;84(4 suppl):S51–S69.
- Lockhart PB, Bolger AF, Papapanou PN, et al. Periodontal disease and atherosclerotic vascular disease: does the evidence support an independent association? A scientific statement from the American Heart Association. *Circulation.* 2012;125(20):2520–2544.
- Prochnau D, Lehmann M, Straube E, Figulla HR, Rödel J. Human cytomegalovirus induces MMP-1 and MMP-3 expression in aortic smooth muscle cells. *Acta Microbiol Immunol Hung.* 2011;58(4):303–317.
- Bartruff JB, Yukna RA, Layman DL. Outer membrane vesicles from *Porphyromonas gingivalis* affect the growth and function of cultured human gingival fibroblasts and umbilical vein endothelial cells. *J Periodontol.* 2005;76(6):972–979.
- Fitzpatrick RE, Wijeyewickrema LC, Pike RN. The gingipains: scissors and glue of the periodontal pathogen, *Porphyromonas gingivalis*. *Future Microbiol.* 2009;4(4):471–487.
- Oscarsson J, Karched M, Thay B, Chen C, Asikainen S. Proinflammatory effect in whole blood by free soluble bacterial components released from planktonic and biofilm cells. *BMC Microbiol.* 2008;8:206.
- D'Aiuto F, Orlandi M, Gunsolley JC. Evidence that periodontal treatment improves biomarkers and CVD outcomes. *J Periodontol.* 2013;84(4 suppl):S85–S105.
- Blake GJ, Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. *J Intern Med.* 2002;252(4):283–294.
- Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation: aspirin, and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med.* 1997;336(14):973–979.
- Freitas CO, Gomes-Filho IS, Naves RC, et al. Influence of periodontal therapy on C-reactive protein level: a systematic review and meta-analysis. *J Appl Oral Sci.* 2012;20(1):1–8.
- Higashi Y, Goto C, Hidaka T, et al. Oral infection-inflammatory pathway: periodontitis, is a risk factor for endothelial dysfunction in patients with coronary artery disease. *Atherosclerosis.* 2009;206(2):604–610.
- Armitage GC. The complete periodontal examination. *Periodontol.* 2004;2000(34):22–33.